C
Chloe Orkin
Researcher at Queen Mary University of London
Publications - 229
Citations - 14129
Chloe Orkin is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 11614 citations. Previous affiliations of Chloe Orkin include Barts Health NHS Trust & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control.
Erik M. Volz,Le Vu S,Oliver Ratmann,Anna Tostevin,David Dunn,Chloe Orkin,O'Shea S,Delpech,Alison E Brown,Noel Gill,Christophe Fraser +10 more
TL;DR: A large number of young men who have sex with men in the United Kingdom have greater risk of infection and higher risk of transmission to other young MSM, which has implications for design of pre-exposure prophylaxis public health initiatives.
Journal ArticleDOI
Factors influencing lopinavir and atazanavir plasma concentration
Wolfgang Stöhr,David Back,David Dunn,Caroline A. Sabin,Alan Winston,Richard Gilson,Deenan Pillay,Teresa Hill,Jonathan Ainsworth,Brian Gazzard,Clifford Leen,Loveleen Bansi,Martin Fisher,Chloe Orkin,Jane Anderson,Margaret A. Johnson,Philippa Easterbrook,Sara Gibbons,Saye Khoo +18 more
TL;DR: This analysis confirms that efavirenz decreases atazanavir concentrations, and there was a negative association of weight and lopinavir concentrations.
Journal ArticleDOI
Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
TL;DR: Key clinical aspects of emergent resistance to DTG among treatment-naive and treatment-experienced INSTI-naïve patients are focused on with an aim to inform clinical decision-making.
Journal ArticleDOI
Monkeypox
Oriol Mitjà,Dimie Ogoina,Boghuma K Titanji,Cristina Galván,Jean-Jacques Muyembe,Michael Marks,Chloe Orkin +6 more
TL;DR: In this article , Central Medical College Journal Vol 5 No 2, No 2 Jul 2021 PP 66, p. 978-0D; CMCJV5.0D.
Journal ArticleDOI
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz
Anna Maria Geretti,Tim Conibear,Andrew Hill,Jeffrey A. Johnson,Lotke Tambuyzer,Kim Thys,Johan Vingerhoets,Yvon van Delft,Armin Rieger,N. Vetter,R. Greil,Christian N. S. Pedersen,M. Storgaard,Philippe Morlat,Christine Katlama,J. Durant,Laurent Cotte,Claudine Duvivier,David Rey,Stefan Esser,C. Stellbrink,W. Schmidt,M. Stoll,Christoph Stephan,Gerd Fätkenheuer,Albrecht Stoehr,Juergen K. Rockstroh,Dénes Bánhegyi,L. Itzchak,E. Shahar,S. Maayan,Dan Turner,Adriano Lazzarin,A. Antinori,G. Carosi,Lorenzo Minoli,G. Di Perri,Gaetano Filice,M. Andreoni,D. Duiculescu,Sorin Rugină,S. Erscoiu,A. Streinu,A. Pronin,Vadim Pokrovsky,B. Gruzdev,A. Yakovlev,Evgeniy Voronin,B Clotet,Gatell Jm,Jose R. Arribas,Daniel Podzamczer,Pere Domingo,C. Miralles Alvarez,J. Hernandez Quero,Hansjakob Furrer,J. Feher,Margaret A. Johnson,Julie Fox,Mark T. Nelson,M Fisher,Chloe Orkin +61 more
TL;DR: The detection of resistance increased marginally with PBMC testing but did not increase with sensitive plasma testing, and a careful consideration is required of the cost-effectiveness of different strategies for baseline HIV drug resistance testing.